FDA Approves ZYRTEC-D — Kenvue Brands LLC

Kenvue Brands LLC secured a competitive edge in the oral allergy market with the 2001 FDA approval of ZYRTEC-D, allowing the company to leverage a branded combination of cetirizine and pseudoephedrine against a backdrop of increasing generic competition.